Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 20.83% is 309% above its 5-year average of -9.97%, near the high end of its 5-year range (-40.76%–20.83%).
653.35% above its 12-month average of 2.76%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 20.76%.
RETURN ON ASSETS (ROA)
20.83%
RETURN ON ASSETS (ROA) AVG TTM
2.76%
RETURN ON ASSETS (ROA) AVG 3Y
-12.34%
RETURN ON ASSETS (ROA) AVG 5Y
-9.97%
RETURN ON ASSETS (ROA) AVG 10Y
-22.96%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+653.35%
CURRENT VS 3Y AVG
+268.87%
CURRENT VS 5Y AVG
+308.89%
CURRENT VS 10Y AVG
+190.73%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+171.53%
vs the sector median at left
CareDx, Inc
Market Cap
$3.39B
Return on Assets (ROA)
20.83%
TTM Avg
2.76%
3Y Avg
-12.34%
5Y Avg
-9.97%
Market Cap
$3.42B
Return on Assets (ROA)
21.83%
TTM Avg
22.04%
3Y Avg
-0.21%
5Y Avg
-10.13%
Market Cap
$3.45B
Return on Assets (ROA)
-27.35%
TTM Avg
-41.78%
3Y Avg
-34.97%
5Y Avg
-41.24%
Market Cap
$3.47B
Return on Assets (ROA)
-13.36%
TTM Avg
-17.34%
3Y Avg
-16.80%
5Y Avg
-15.30%
Market Cap
$3.53B
Return on Assets (ROA)
-1.28%
TTM Avg
-8.27%
3Y Avg
-17.73%
5Y Avg
-16.90%
Market Cap
$3.05B
Return on Assets (ROA)
5.84%
TTM Avg
-21.93%
3Y Avg
-47.49%
5Y Avg
-47.67%
Market Cap
$3.03B
Return on Assets (ROA)
-44.17%
TTM Avg
-37.77%
3Y Avg
-27.61%
5Y Avg
-21.12%
Market Cap
$3.02B
Return on Assets (ROA)
-57.49%
TTM Avg
-99.67%
3Y Avg
-60.13%
5Y Avg
-103.92%
Market Cap
$2.96B
Return on Assets (ROA)
-11.64%
TTM Avg
-24.55%
3Y Avg
-30.16%
5Y Avg
-27.23%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CareDx, Inc (CDNA) | $3.39B | 20.83% | 2.76% | -12.34% | -9.97% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.42B | 21.83% | 22.04% | -0.21% | -10.13% |
| Celcuity Inc. (CELC)vs › | $3.45B | -27.35% | -41.78% | -34.97% | -41.24% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.47B | -13.36% | -17.34% | -16.80% | -15.30% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | -1.28% | -8.27% | -17.73% | -16.90% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 5.84% | -21.93% | -47.49% | -47.67% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.03B | -44.17% | -37.77% | -27.61% | -21.12% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.02B | -57.49% | -99.67% | -60.13% | -103.92% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.96B | -11.64% | -24.55% | -30.16% | -27.23% |
| ICU Medical, Inc. (ICUI)vs › | $3.96B | 0.76% | -1.39% | -1.28% | 0.88% |
ROA
20.8%
ROE
26.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -5.17% |
| 2024-12-31 | 10.70% |
| 2023-12-31 | -40.76% |
| 2022-12-31 | -14.11% |
| 2021-12-31 | -5.41% |
| 2020-12-31 | -5.08% |
| 2019-12-31 | -14.48% |
| 2018-12-31 | -35.77% |
| 2017-12-31 | -66.38% |
| 2016-12-31 | -51.44% |
| 2015-12-31 | -24.64% |
| 2014-12-31 | 1.28% |
| 2013-12-31 | -35.88% |
| 2012-12-31 | -51.23% |
